U.S. Gold Corp. (USAU)

Lumos Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Net Income	-20.56	-6.9	-7.61	-13.93	-12.39
Depreciation & Amortization	0.12	0.12	0.11	0.1	0.1
Loss (Gain) From Sale of Assets	-	-	-0.76	-	-
Stock-Based Compensation	2.17	0.82	1.68	2.2	3.64
Other Operating Activities	7.71	-0.32	-1.3	-1.21	-
Change in Inventory	0.17	0.03	-	-	-
Change in Accounts Payable	0.33	0.04	-0.73	0.47	0.35
Change in Income Taxes	-	-	-	-	0.22
Change in Other Net Operating Assets	0.19	-0.86	-0.08	-0.2	-0.51
Operating Cash Flow	-9.87	-7.08	-8.69	-12.58	-8.59
Capital Expenditures	-0.01	-	-0.18	-0.18	-0.04
Sale of Property, Plant & Equipment	-	-	2.75	-	-
Cash Acquisitions	-	-	-	-	2.5
Investing Cash Flow	-0.01	-	2.57	-0.18	2.46
Issuance of Common Stock	12.47	4.83	4.83	8.22	11.5
Financing Cash Flow	12.47	4.83	4.83	8.22	17.03
Net Cash Flow	2.59	-2.25	-1.29	-4.53	10.9
Free Cash Flow	-9.88	-7.08	-8.87	-12.75	-8.63
Free Cash Flow Per Share	-0.86	-0.76	-1.05	-1.76	-1.83
Levered Free Cash Flow	-5.17	-3.88	-4.82	-7.12	-3.58
Unlevered Free Cash Flow	-5.17	-3.88	-4.82	-7.12	-3.58

Updated Jul 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q